Cartesian Therapeutics Files 8-K
Ticker: RNAC · Form: 8-K · Filed: May 22, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financial-statements
TL;DR
Cartesian Therapeutics filed an 8-K, mostly routine stuff, check financials.
AI Summary
On May 22, 2024, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and Regulation FD disclosures. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates routine corporate reporting, including financial statements and other disclosures, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate material adverse events or significant financial changes.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- May 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37798 (identifier) — Commission File Number
- 704 Quince Orchard Road, Gaithersburg, MD 20878 (address) — Address of principal executive offices
- 617-923-1400 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Cartesian Therapeutics, Inc.?
The filing serves as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated May 22, 2024.
In which state is Cartesian Therapeutics, Inc. incorporated?
Cartesian Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Cartesian Therapeutics, Inc.?
The Commission File Number for Cartesian Therapeutics, Inc. is 001-37798.
What is the address of Cartesian Therapeutics, Inc.'s principal executive offices?
The address of Cartesian Therapeutics, Inc.'s principal executive offices is 704 Quince Orchard Road, Gaithersburg, MD 20878.
Filing Stats: 587 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-22 07:08:48
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
Filing Documents
- rnac-20240522.htm (8-K) — 31KB
- rnac_05222024xrmatdesignat.htm (EX-99.1) — 14KB
- image_0.jpg (GRAPHIC) — 111KB
- 0001453687-24-000084.txt ( ) — 327KB
- rnac-20240522.xsd (EX-101.SCH) — 2KB
- rnac-20240522_lab.xml (EX-101.LAB) — 22KB
- rnac-20240522_pre.xml (EX-101.PRE) — 13KB
- rnac-20240522_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On May 22, 2024, Cartesian Therapeutics, Inc. ("the Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has granted Regenerative Medicine Advanced Therapeutic ("RMAT") designation for Descartes-08 for the treatment of myasthenia gravis ("MG"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On May 22, 2024, the Company announced that the FDA granted RMAT designation for Descartes-08 for the treatment of MG. Descartes-08, the Company's lead product candidate, is an autologous mRNA CAR-T directed against the-B cell maturation antigen initially being developed for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Press Release Issued by Cartesian Therapeutics, Inc. on May 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: May 22, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer